Gene and Cell Therapy · us
Editing Hematopoietic Stem Cells to Support Multiple Organs: Progress in a Friedreich’s Ataxia Mouse Study
A single infusion of CRISPR-corrected cells improved motor performance, heart tissue, and pancreatic islets in mice with the disease. This approach to supporting organs throughout the body through blood cells now has animal proof of concept, but hurdles remain before it can reach patients.
The damage caused by Friedreich’s ataxia has never been limited to walking. This inherited disease also affects the heart and pancreas, creating a treatment challenge that spans multiple organs. A mouse study offers a new lead: correcting hematopoietic stem cells may allow their descendants, distributed throughout tissues, to support several damaged organs at once.
In a study published October 15 in the Journal of Clinical Investigation, Anusha Sivakumar and colleagues used CRISPR/Cas9 to remove abnormal GAA repeats that suppress FXN gene expression from hematopoietic stem and progenitor cells outside the body. They then infused the cells into mice carrying a disease-causing human FXN gene after irradiation to ablate the bone marrow. Following a single infusion, the transplanted cells persisted long term and increased frataxin protein expression in the relevant tissues.
The mice showed improved motor performance and protection of cerebellar structure. Some measures of cardiac structure and inflammation also improved, while the number of insulin-producing β cells in pancreatic islets increased. However, each finding has limits: cardiac hypertrophy did not disappear, and fasting blood glucose had shown no significant differences among the groups to begin with, so the islet changes cannot be directly interpreted as a reversal of diabetes.
Lucy R. Osborne, author of an accompanying commentary, noted that the key to this strategy lies in macrophages and microglia-like cells derived from the transplanted cells. They support affected tissues, alongside reductions in mitochondrial stress and inflammatory signaling, allowing the research to proceed without first editing individual neurons or heart muscle cells. The commentary characterizes the findings as preclinical proof of concept supporting translation to humans.
Background and Context
At the core of the disease is a shortage of frataxin, which disrupts mitochondrial function and particularly damages tissues such as the nervous system and heart. Delivering treatment to different organs has long been a challenge for gene therapy. Editing cells outside the body and then transplanting them offers another route to systemic intervention, while extending the use of hematopoietic cells beyond the blood.
However, protecting organs does not mean that all existing damage can be repaired. Osborne cautioned that treatment improved gait but did not reverse neuronal loss that had already occurred. Heart disease in these mice was also relatively mild, leaving the study unable to answer whether the approach could prevent heart failure in patients. The timing of treatment may influence its effectiveness as much as the editing itself.
Before moving into humans, researchers still need to address editing efficiency, cell engraftment, off-target risks, and bone marrow ablation procedures. “A single infusion” describes how the treatment was administered in the animal experiment; it does not mean that the treatment process is simple or that long-term benefits for patients have been established. This work advances the idea of treating multiple organs to the stage of testable animal evidence.